Man Group plc Has $1.57 Million Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Man Group plc trimmed its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 60.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 354,824 shares of the biotechnology company’s stock after selling 539,902 shares during the quarter. Man Group plc owned about 0.22% of Ironwood Pharmaceuticals worth $1,572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $45,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $47,000. Envestnet Asset Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $50,000. Xponance Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $53,000.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IRWD shares. Craig Hallum downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. JMP Securities dropped their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Citizens Jmp downgraded Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 14th. Leerink Partners dropped their price target on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating on the stock in a research note on Monday, April 14th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $1.00 price target (down from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $4.78.

Ironwood Pharmaceuticals Stock Down 8.7%

Shares of Ironwood Pharmaceuticals stock opened at $0.57 on Friday. The company has a market cap of $91.64 million, a PE ratio of -18.88 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.53 and a 52 week high of $7.11. The business has a 50 day moving average price of $0.98 and a 200-day moving average price of $2.43.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The company had revenue of $41.14 million during the quarter, compared to analysts’ expectations of $67.02 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. As a group, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.